Head-To-Head Review: WAVE Life Sciences (NASDAQ:WVE) and Ligand Pharmaceuticals (NASDAQ:LGND)

Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) and WAVE Life Sciences (NASDAQ:WVE – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Insider and Institutional Ownership

91.3% of Ligand Pharmaceuticals shares are held by institutional investors. Comparatively, 89.7% of WAVE Life Sciences shares are held by institutional investors. 5.6% of Ligand Pharmaceuticals shares are held by insiders. Comparatively, 24.3% of WAVE Life Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Ligand Pharmaceuticals and WAVE Life Sciences”s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Ligand Pharmaceuticals $268.09 million 21.40 $124.45 million $2.24 128.07
WAVE Life Sciences $42.73 million 11.82 -$204.38 million ($1.07) -2.39

Ligand Pharmaceuticals has higher revenue and earnings than WAVE Life Sciences. WAVE Life Sciences is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Ligand Pharmaceuticals has a beta of 1.16, indicating that its stock price is 16% more volatile than the S&P 500. Comparatively, WAVE Life Sciences has a beta of -1.4, indicating that its stock price is 240% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Ligand Pharmaceuticals and WAVE Life Sciences, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ligand Pharmaceuticals 0 1 8 0 2.89
WAVE Life Sciences 1 2 15 2 2.90

Ligand Pharmaceuticals currently has a consensus target price of $355.38, indicating a potential upside of 23.88%. WAVE Life Sciences has a consensus target price of $20.44, indicating a potential upside of 698.61%. Given WAVE Life Sciences’ stronger consensus rating and higher possible upside, analysts clearly believe WAVE Life Sciences is more favorable than Ligand Pharmaceuticals.

Profitability

This table compares Ligand Pharmaceuticals and WAVE Life Sciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Ligand Pharmaceuticals 20.27% 5.22% 2.74%
WAVE Life Sciences -296.86% -44.66% -36.80%

Summary

Ligand Pharmaceuticals beats WAVE Life Sciences on 10 of the 15 factors compared between the two stocks.

About Ligand Pharmaceuticals

(Get Free Report)

Ligand Pharmaceuticals is a biopharmaceutical company that works with pharmaceutical and biotechnology partners to develop and commercialize medicines. Rather than focusing primarily on selling drugs directly, Ligand licenses technologies and drug-development assets and may receive royalties and other payments from partner programs. Its technologies include Captisol, a formulation platform designed to improve the solubility and delivery of certain medicines. Ligand also holds economic interests in a portfolio of partnered products and drug candidates across multiple therapeutic areas.

About WAVE Life Sciences

(Get Free Report)

WAVE Life Sciences Ltd. is a biotechnology company developing RNA-based medicines for genetically defined diseases. Founded in 2012, the company is headquartered in Cambridge, Massachusetts, and uses its oligonucleotide chemistry and drug-design capabilities to develop treatments intended to alter or regulate gene expression. Its research includes antisense oligonucleotide therapies and RNA-editing approaches. Programs have targeted conditions such as Huntington’s disease and alpha-1 antitrypsin deficiency, with the latter exploring RNA editing to address a disease-causing genetic variant.

Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.